“Colorectal cancer is still one of the most frequent and deadliest cancers worldwide. But diagnosed in time it can be cured in 9 out of 10 cases,” said Professor Serge Haan from the Life Science Research Unit at the University of Luxembourg…
In what is believed to be the first comprehensive examination of trends in cardiac stress testing utilizing imaging, researchers also showed that there are no significant racial or ethnic health disparities in its use. They also made national estimates of the cost of unnecessary cardiac stress testing with imaging and the health burden of this testing, in terms of cancer risk due to radiation exposure. Cardiac stress testing, particularly with imaging, has been the focus of debate about rising health care costs, inappropriate use, and patient safety in the context of radiation exposure…
Coffee consumption is highly prevalent with more than half of all Americans over 18 drinking on average three cups each day according to a 2010 report from the National Coffee Association. Moreover, the International Coffee Association reports that coffee consumption has increased one percent each year since the 1980s, increasing to two percent in recent years. Previous studies found that coffee consumption may help lower the risk of developing diabetes, cardiovascular disease, non-alcoholic fatty liver disease, cirrhosis, and liver cancer…
Although salivary gland cancer is rare, this retrospective study suggests it occurs 17 times more often in people with inherited mutations in genes called BRCA1 and BRCA2, than those in the general population. “Further study is needed to confirm this preliminary result, but I believe that a BRCA-positive patient with a lump in a salivary gland should have that lesion evaluated as soon as possible,” says co-author Theodoros Teknos, MD, professor and chair of otolaryngology, director of head and neck oncologic surgery, and the David E…
The team of investigators from Memorial Sloan Kettering Cancer Center, New York City, analyzed data from the National Cancer Data Base (NCDB) of the American College of Surgeons and the American Cancer Society, and looked at more than 1 million women who underwent mastectomy due to breast cancer between 1998 and 2011. …
Assessing if and how far breast cancer has spread throughout the body is what doctor’s refer to as staging. …
They used the platform to identify a novel antibody that is undergoing further investigation as a potential treatment for breast, ovarian and other cancers. In research published online in the Proceedings of the National Academy of Sciences, researchers in the lab of Stephen Weiss at the U-M Life Sciences Institute detail an approach that replicates the native environment of cancer cells and increases the likelihood that drugs effective against the growth of tumor cells in test tube models will also stop cancer from growing in humans. The researchers have used their method to identify an antibody that stops breast cancer tumor growth in animal models, and they are investigating the antibody as a potential treatment in humans. “Discovering new targets for cancer therapeutics is a long and tedious undertaking, and identifying and developing a potential drug to specifically hit that target without harming healthy cells is a daunting task,” Weiss said. …
In a major study, Dr Ian Frayling from Cardiff University’s School of Medicine and researchers from the University of Exeter’s Medical School assessed the effectiveness of introducing a UK-wide screening program for a genetic condition known as Lynch Syndrome. Lynch syndrome is caused by changes in genes which check the spelling in DNA. The condition increases the risk of people developing cancer, particularly bowel cancer and cancers of the womb and ovaries later in life. …
This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …
This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. Dr. Perez is co-chair of ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study). …